Effective induction of type 1 helper IgG2a and cytotoxic T-Cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59

Viral Immunology

Volumn 21, Issue 2, 2008, Pages 225-233

  Heinemann, Lucy ^a   Woodfield, Lauren ^a   Amer, Mira ^a   Hibma, Merilyn ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN E2; IMMUNOGLOBULIN G2A; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; VIRUS ANTIGEN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CARBOXY TERMINAL SEQUENCE; CELL POLARITY; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROVOCATION TEST; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; DNA-BINDING PROTEINS; FEMALE; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; POLYSORBATES; SQUALENE; T-LYMPHOCYTES, CYTOTOXIC;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MUS; PAPILLOMAVIRIDAE;

EID: 45749091342     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0101     Document Type: Conference Paper

References (31)

1. Beck L, and Spiegelberg HL: The polyclonal and antigen-specific IgE and IgG subclass response of mice injected with ovalbumin in alum or complete Freund's adjuvant. Cell Immunol 1989;123:1-8.
2. Bontkes HJ, de Gruijl TD, Bijl A, et al.: Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol 1999;80:2453-2459.
3. Bosch FX, Manos MM, Munoz N, et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
4. Boyce TG, Hsu HH, Sannella EC, et al.: Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000;19:217-226.
5. Broker TR, Jin G, Croom-Rivers A, et al.: Viral latency - the papillomavirus model. Dev Biol (Basel) 2001;106:443-451; discussion 452-453, 465-475.
6. Cohen J: Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 2005;308:618-621.
7. Constant S, Pfeiffer C, Woodard A, Pasqualini T, and Bottomly K: Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J Exp Med 1995;182:1591-1596.
8. Constant SL, and Bottomly K: Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997;15:297-322.
9. de Jong A, van der Burg SH, Kwappenberg KM, et al.: Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62:472-479.
10. de Jong A, van Poelgeest MI, van der Hulst JM, et al.: Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-5455.
11. Dillon S, Sasagawa T, Crawford A, Prestidge J, Inder MK, Jerram J, Mercer AA, and Hibma M: Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2. J Gen Virol 2007;88:803-813.
12. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, and Stevenson PG: Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997;159:105-117.
13. Frazer IH: Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46-54.
14. Harper DM, Franco EL, Wheeler CM, et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-1255.
15. Heineman TC, Clements-Mann ML, Poland GA, et al.: A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999;17:2769-2778.
16. Heinemann L, Dillon S, Crawford A, Backstrom BT, and Hibma MH: Flow cytometric quantitation of the protective efficacy of dendritic cell based vaccines in a human papillomavirus type 16 murine challenge model. J Virol Methods 2004;117:9-18.
17. Herbert WJ : Mineral-oil adjuvants and the immunization of laboratory animals. In: Handbook of Experimental Immunology, 2nd ed. (Weir DM, ed.). Blackwell Scientific Publications, Oxford, 1973, pp. A2.1-A2.14.
18. Hibma MH, Raj K, Ely SJ, Stanley M, and Crawford L: The interaction between human papillomavirus type 16 E1 and E2 proteins is blocked by an antibody to the N-terminal region of E2. Eur J Biochem 1995;229:517-525.
19. Katayama S, Oda K, Ohgitani T, Hirahara T, and Shimizu Y: Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice. Vaccine 1999;17:2733-2739.
20. Mao C, Koutsky LA, Ault KA, et al.: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
21. Menegon T, Baldo V, Bonello C, Dalla Costa D, Di Tommaso A, and Trivello R: Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999;15:573-576.
22. Morel PA, and Oriss TB: Crossregulation between Th1 and Th2 cells. Crit Rev Immunol 1998;18:275-303.
23. Nichol KL, and Treanor JJ: Vaccines for seasonal and pandemic influenza. J Infect Dis 2006;194(Suppl 2):S111-S118.
24. Podda A: The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-2680.
25. Schmitt A, Rochat A, Zeltner R, Borenstein L, Barrandon Y, Wettstein FO, and Iftner T: The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. J Virol 1996;70:1912-1922.
26. Secrist H, DeKruyff RH, and Umetsu DT: Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-1089.
27. Singh M, Carlson JR, Briones M, et al.: A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998;16: 1822-1827.
28. Valensi JP, Carlson JR, and Van Nest GA: Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994;153:4029-4039.
29. van Poelgeest MI, Nijhuis ER, Kwappenberg KM, et al.: Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 2006;118:675-683.
30. Woodland DL: Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004;25:98-104.
31. Zhu X, Tommasino M, Vousden K, et al.: Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. Scand J Immunol 1995;42:557-563.